1 1
Out of Stock

Wegovy (Semaglutide) Injection Pen 1 mg, 1 Ct - Novo Nordisk

Wegovy (Semaglutide) Injection Pen 1 mg, 1 Ct - Novo Nordisk

PKR 31,945
PKR 31,945
Out of Stock
Pack Size: 1 x 3mL pen & 4 disposable needles
Wegovy 1 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the third step in the standard dose‑escalation schedule for chronic weight management. It is indicated for...  Read More
Brand: Novo Nordisk
SKU: 05712249132798
Availability: In Stock
Country: Pakistan
View full details

Description

Wegovy 1 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the third step in the standard dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27. The 1 mg dose is taken once weekly during weeks 9‑12 of treatment as part of the 16‑week titration protocol.

  • Moderate Therapeutic Dose for Weight Loss: The 1 mg dose (weeks 9‑12) is the third step in the Wegovy titration schedule, where meaningful weight loss begins—patients can expect appetite suppression of 25‑35% and improved insulin sensitivity, with weight loss of 5‑8% total body weight by week 12
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1 mg dose playing a key role in gradually building tolerance before reaching the target dose
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 4 mg semaglutide in 3 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy 1 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the third step in the standard dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27. The 1 mg dose is taken once weekly during weeks 9‑12 of treatment as part of the 16‑week titration protocol.

  • Moderate Therapeutic Dose for Weight Loss: The 1 mg dose (weeks 9‑12) is the third step in the Wegovy titration schedule, where meaningful weight loss begins—patients can expect appetite suppression of 25‑35% and improved insulin sensitivity, with weight loss of 5‑8% total body weight by week 12
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1 mg dose playing a key role in gradually building tolerance before reaching the target dose
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 4 mg semaglutide in 3 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy 1 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist pen used as the third step in the standard dose‑escalation schedule for chronic weight management. It is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27. The 1 mg dose is taken once weekly during weeks 9‑12 of treatment as part of the 16‑week titration protocol.

  • Moderate Therapeutic Dose for Weight Loss: The 1 mg dose (weeks 9‑12) is the third step in the Wegovy titration schedule, where meaningful weight loss begins—patients can expect appetite suppression of 25‑35% and improved insulin sensitivity, with weight loss of 5‑8% total body weight by week 12
  • Foundation for Clinically Proven Weight Loss: When followed through to the 2.4 mg maintenance dose, Wegovy produced a mean weight loss of up to 15.6% in the STEP UP trial, with the 1 mg dose playing a key role in gradually building tolerance before reaching the target dose
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal heart attack, or non‑fatal stroke) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: Administer subcutaneously once weekly in the abdomen, thigh, or upper arm, at any time of day, with or without meals

Composition
Each prefilled pen contains 4 mg semaglutide in 3 mL (1.34mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.